



2009 Corporate Citizenship Report

Driving Toward a Sustainable Future

Letter from Leadership



Robert A. Hamm, Chief Operating Officer

At Biogen Idec, we believe that in order for society to be sustainable, it must address the long-term implications of its actions on the economic, environmental and societal resources needed to ensure human well-being. This task is significant, and we believe that one individual or group cannot address all of the world's economic, environmental and social needs working alone.

For society to achieve sustainability, corporations must be accountable for their actions and conduct their affairs responsibly and with transparency; they must be good corporate citizens. Our 2009 Corporate Citizenship Report details some of our past and current sustainability efforts and documents Biogen Idec's commitment to our stakeholders, including our patients, employees, shareholders, the environment, and the communities where we live and work.

This report has three sections that incorporate the main elements of sustainability as they apply to Biogen Idec: Business, Environment and Society.

Business: Operating with ethics, integrity and accountability is integral to our success. As part of our efforts to build long-term value for our shareholders, we make substantial investments in research and development to discover new therapies.

Environment: Recognizing that the development, manufacture and distribution of our products use natural resources, consume energy and generate waste, we are working to minimize these impacts across our enterprise.

Society: We are addressing some of the greatest unmet medical needs; providing educational and other support services for our patients; offering a supportive and challenging work environment to our employees; and giving back to the communities where we live and work.

The title of this report, "Driving Toward a Sustainable Future," aptly conveys our sense of mission, our innovative spirit, and our belief in the potential of what our future direction and discoveries may someday bring. It is with great pride that we provide this report for your review and invite you to share your feedback at corporatecitizenshipreport@biogenidec.com.

Sincerely,

A handwritten signature in black ink, appearing to read "Robert A. Hamm". The signature is fluid and cursive.

Robert A. Hamm
Chief Operating Officer
Chairman of Biogen Idec's Sustainability Council

SUSTAINABILITY



About the Report ▶▶

This corporate citizenship report, Biogen Idec's first, outlines our definition of and journey toward sustainability to our employees and key stakeholders. This report was prepared in accordance with the Global Report Initiative (GRI) G3 Guidelines, a voluntary framework to guide organizations reporting on their economic, environmental and social performance. The GRI Guidelines are the most commonly used global reporting framework and help facilitate rigor, transparency and accountability in Corporate Citizenship reporting by organizations regardless of size, sector or location.

Under the GRI G3 Guidelines, organizations must self-declare the level to which they have applied the GRI Guidelines, designated via an Application Level of C, B or A where A represents the most comprehensive level of reporting. For our first report, Biogen Idec has achieved an Application Level of C. We plan to publish subsequent reports annually. For additional information, please refer to: www.globalreporting.org.

Data in this report covers calendar years 2006 through 2009, with an emphasis on 2009 activities. All references to currency are in United States dollars. Biogen Idec is responsible for the preparation and integrity of the content in this report. Through a system of internal controls, including a comprehensive verification process by internal subject matter experts, we believe this report accurately represents our corporate citizenship initiatives.

Throughout this report, "Biogen Idec," "we," "us," and "our" refer to Biogen Idec and its consolidated subsidiaries; "RITUXAN" refers to both RITUXAN (the trade name for rituximab in the United States, Canada and Japan) and MabThera (the trade name for rituximab outside the United States, Canada and Japan). AVONEX® and RITUXAN® are registered trademarks of Biogen Idec or its subsidiaries. TYSABRI® is a registered trademark of Elan Pharmaceuticals, Inc.

Chapters	Page	GRI Indicators
About the Report	3	2.1, 3.1 – 3.3, 3.13
Business	4	1.2, 2.2 – 2.8, 3.5,
About Our Company	4	4.1 – 4.4, 4.6, 4.8,
Corporate Governance	5	4.9, 4.12 – 4.17,
Environment	7	EC1^, LA1^, SO5
Environmental Stewardship	7	EC2, EN5^, EN6,
Society	11	EN7, EN18, EN26^
Medicines for Unmet Needs	11	EC3, LA2^, LA7 –
Workplace Culture	13	8, LA11, PR1, PR6,
Philanthropy	15	EC8



Self-Rating

Based on GRI G3 application level criteria, we rate our report a C.

Notes:

- * Indicators included in the Letter from Leadership include: 1.1, 3.4
- * Indicators not applicable for this report include: 2.9, 3.7 – 3.8, 3.10 – 3.11, LA6
- * Indicators determined not to be material include: EN11 – 15, EN19 – 21, EN23 – 25, EN27, EN29, HR6 – 9
- * Indicators provided throughout the report include: 2.10, 3.6 and 3.9
- ^ Partial coverage



On the Cover:

Biogen Idec employees team with San Diego middle school teachers and students to conduct hands-on science experiments as part of the Biogen Idec Community Labs program.

Business



The **Business** focus of sustainability at Biogen Idec is about living our values and holding ourselves to the highest standards of ethics and integrity. We work to deliver value to our shareholders and invest in research and development for continued business growth.

About Our Company ▶▶

Founded in 1978, Biogen Idec is a leader in the discovery and development of innovative therapies to meet high, unmet medical needs, including treatments for multiple sclerosis (MS), lymphoma and rheumatoid arthritis. The company, headquartered in Weston, Mass., and internationally in Zug, Switzerland, employs more than 4,700 people worldwide.

Biogen Idec's operations are focused on the manufacture of biologics. Our products are distributed worldwide and include TYSABRI (natalizumab), a treatment for relapsing forms of MS that is also approved in the United States for Crohn's disease; AVONEX (interferon beta-1a), one of the leading therapeutic products for relapsing forms of MS worldwide; and RITUXAN (rituximab), a prescribed therapy for non-Hodgkin lymphoma, recently approved for chronic lymphocytic leukemia (CLL) and a proven therapy for rheumatoid arthritis. The company's product pipeline includes nearly 20 products in Phase 2 clinical trials and beyond and addresses our core and emergent therapeutic areas of neurology, oncology, immunology, hemophilia and cardiopulmonary disease.

Our primary manufacturing locations are in Research Triangle Park (RTP), N.C., and Cambridge, Mass. We source all of our fill-finish and the majority of final product storage operations for our products, along with a substantial part of our packaging operations, to third-party contractors. We also execute a portion of packing for the international market in Hillerød, Denmark.

Financial Performance

Fiscal Year (as of December 31)	2006	2007	2008	2009
Operating Results (\$ in millions, except EPS)				
Total Revenues (Sales)	\$2,683.1	\$3,171.6	\$4,097.5	\$4,377.4
GAAP Net Income Attributable to Biogen Idec	\$217.5	\$638.2	\$783.2	\$970.1
GAAP Diluted Earnings Per Share (EPS)	\$0.63	\$1.99	\$2.65	\$3.35
Financial Position (\$ in millions)				
Total Liabilities	\$1,403.0	\$3,094.5	\$2,645.0	\$2,290.0
Total Shareholders' Equity	\$7,149.8	\$5,534.3	\$5,834.0	\$6,261.9
Corporate Statistics				
Number of Employees	3,750	4,300	4,700	4,750

**Forbes' top five
Global High
Performers**

**Forbes' top five
Global High Performers**

Ranked in the top five in the
Drugs and Biotechnology
Industry category, 2009.




Corporate Governance: Our Commitment to Integrity ▶▶

Responsibility for our performance begins with our Board of Directors, which is comprised of 12 directors, a majority of whom meet the independence requirements of the NASDAQ Stock Market. The Board's Corporate Governance Committee sets the governance framework for the company in our Corporate Governance Principles. Additionally, every employee must comply with our Code of Business Conduct, which guides decision making throughout the organization. For more information on our Board, Code of Business Conduct or other governance practices, please visit the "About Us" section of www.biogenidec.com.

Biogen Idec's Sustainability Governance Structure ▶▶

In 2009, we created the Biogen Idec Corporate Sustainability Council (CSC), which is composed of a cross-functional group of executives and is designed to oversee and improve the business, environmental and societal impacts of our global business operations. The CSC met for the first time in February 2009 to define what sustainability means to Biogen Idec and has since worked to develop Biogen Idec's sustainability strategy.

Additionally, in 2009, we created the Biogen Idec Sustainability Leadership Committee to manage the development and implementation of our corporate sustainability initiatives, ensure continued alignment of the global sustainability strategy with the company's mission, and champion sustainability improvements among employees and other stakeholders.



Identifying Our Opportunities and Risks >>

One of the CSC's first steps was to assess the key citizenship risks and opportunities that are most important to both our business and our stakeholders. To assess our performance, we reviewed numerous sources, including corporate strategic plans, employee surveys, media coverage and Socially Responsible Investment Fund evaluations, to name a few. The table to the right summarizes the findings of our assessment and issues discussed in this report.



Engaging with Stakeholders >>

We believe that engaging in constructive dialogue with our stakeholders, including patients, doctors, employees, investors, communities, suppliers and partners, is critical for our long-term success. These relationships provide us with new perspectives and valuable information that help us identify issues and improve our performance. We collect feedback on an ongoing basis through established channels in government relations, investor relations and patient services, as well as hold individual meetings with other organizations as necessary. We also belong to a number of industry organizations, which share best practices within and outside our industry. Some of these groups include:

- Global Environmental Management Initiative (GEMI)
- ORC Worldwide: Global Human Resource Solutions (ORC)
- Pharmaceutical Supply Chain Initiative (PSCI)
- BioPharma EHS Forum
- Corporate Responsibility Officer Association (CROA)

We continually engage in active discussions with our shareholders. We aim to work with our Board members to continue to build on our solid track record of strong financial performance. We believe that our focus on our products, robust pipeline and disciplined use of cash will continue to drive long-term value for our shareholders.

Public Policy: Biogen Idec participates in public-policy discussions that we believe benefit our patients and foster innovation and growth in the industry. Biogen Idec does not make federal political contributions; however, our employee-funded Political Action Committee does contribute to individual federal candidates working to advance the public-policy goals of the industry. By law, these contributions are publicly disclosed on the Federal Election Commission's Web site at www.fec.gov.

Environment



The **Environment** focus of sustainability at Biogen Idec is about protecting our planet's resources. Recognizing that the development, manufacture and distribution of our products use natural resources, consume energy and generate waste, we are working to minimize these impacts across all areas of our enterprise.




Environmental Stewardship ▶▶

For years, we've developed innovative solutions to lessen our impact on the planet while operating our business efficiently. In 2009, we undertook a comprehensive review of our environmental practices and developed a long-term strategy to continue to improve our performance. We also began implementing an Environmental Management Information System to track our performance over time.

Biogen Idec 2015 Environmental Performance Goal

In 2009, Biogen Idec established a risk-weighted environmental index to track progress against reducing our environmental footprint in four key areas: water use, energy intensity, greenhouse gas emissions (GHG) and solid waste to landfill. To develop the index, we considered the importance of these resources to our business and the environment. For example, water is a key input to our operations and is also scarce in some regions where we operate, so we weighted water use more heavily in our overall environmental footprint. We then set a goal of reducing our overall footprint by 15 percent by 2015 compared to our 2006 baseline.

Biogen Idec Risk-Weighted Environmental Index



Reducing Water Use ►►

Water is an essential resource in our manufacturing processes. We recognize the importance of this valuable resource and strive to optimize, recycle and reuse it whenever possible.

Saving Water in Cambridge: Our Cambridge campus reduced its annual water use by an average of 8.3 million gallons through reusing water in our cogeneration plant, reclaiming condensate from air conditioning and reusing cooling water from autoclave sterilization cycles.

Reducing Our San Diego Water Footprint: The San Diego campus uses recycled water in its cooling towers, saving five to seven million gallons of potable water per year. Two-thirds of every gallon of water used at the site is recycled or reclaimed.

Looking Forward – Measuring Our Impact In Context

We believe we should evaluate our environmental impacts in the context of what natural systems can sustainably provide. We evaluated the amount of water used in 2009 at our RTP, North Carolina campus in relation to total available renewable water resources. As there are many users of water in the watershed, we also determined the appropriate water allocation for Biogen Idec, given the size of our operations and the value of our economic contributions. Analysis revealed that our water use was well within our allocation. We aim to evaluate more of our environmental footprint 'in context' to ensure that we operate sustainably.



Biogen Idec's 2009 Sustainability Award Winner – RTP Clean-in-Place Acid Elimination and Water Optimization Project

Our new global Sustainability Award is a highly visible way for Biogen Idec to recognize the efforts and positive impacts of our employees. This year's inaugural award was extremely competitive, with nominations submitted from sites around the world.

After much deliberation, the CSC selected the RTP Manufacturing Engineering group for their Clean-in-Place Acid Elimination and Water Optimization program, which worked to eliminate acid from the cleaning cycles throughout the manufacturing plant while reducing and optimizing water use. The results of this effort saved 4.4 million gallons of water in 2009 and \$900,000 in costs from chemical, energy and water reductions. Biogen Idec issued a donation to the Environmental Education Fund on the employees' behalf to support "It's Our Water," a water curriculum that provides environmental education to teachers and students in North Carolina.

Reducing Energy Use and Greenhouse Gas Emissions >>

We strive to conserve energy and leverage efficient technologies and renewable energy sources to minimize consumption and reduce greenhouse gas emissions.

Cogenerating Power in Cambridge:

We built a combined heat and power system that consumes 25 percent less energy, reduces carbon dioxide emissions by 11 percent, saves up to \$4 million annually, and generates on average 75 percent of the electricity and 100 percent of the steam we need at our Cambridge campus each month.

Working Toward Energy Management

Certification in Hillerød, Denmark: We are developing Energy Management Program reduction strategies at our Hillerød, Denmark campus to meet EN16001 certification, the European standard for energy efficiency.


Saving Energy and Reducing Greenhouse Gas Emissions in San Diego:

The San Diego campus implemented several significant projects that reduced energy consumption, including:

- **Central Plant Optimization:** Modifying the chiller from a fixed to variable flow and implementing “night and weekend” setback programs to benefit from free cooling.
- **HVAC Optimization:** Utilizing variable air volume and exhaust fan software to modulate static pressure and control air flow in campus buildings during unoccupied nights and weekends.

A State-of-the-Art Sustainable Headquarters

We moved our headquarters from Cambridge to a new 75-acre campus in Weston, Mass. Working with Boston Properties, we designed a high-tech, green campus that is on track to achieve Leadership in Energy and Environmental Design (LEED) Gold Certification.



- A** Brownfield Site – Built on an old stone quarry, the campus revitalizes a previously vacant parcel of land.
- B** On-site Quarry Ponds – The quarry ponds will be used to cool the building naturally during the summer, which will result in 20 percent less electricity use.
- C** Waste Water Treatment – An on-site treatment plant cleans 100 percent of the waste water from the facility, discharging clean water back into the environment.
- D** Harnessing the Sun – The state's largest ground-mounted photovoltaic solar array (110 kilowatts) powers the waste water treatment plant and generates 80,000 kilowatt-hours per year of extra clean renewable energy that is put back onto the public grid.
- E** Recycling – Single-stream recycling containers throughout the building help employees recycle everyday products. Additionally, cafeteria food and waste are composted.
- F** Green Data Center - Designed with the installation of a high-density rack and self-contained cooling system, our green data center maximizes performance while reducing energy consumption by 35 to 45 percent.

Reducing Solid Waste to Landfills >>

We actively seek new ways to reduce waste and have taken steps to divert waste from landfills.

Forming Green Teams: In Cambridge, San Diego, RTP and Hillerød, employees formed green teams to bring about environmental improvements at our facilities, such as reducing printing and increasing recycling. Green team members also encourage their peers to take small green steps that make a difference.

Composting Waste at RTP: We send our process buffers, which are rich in nitrogen, phosphorous and oxygen, to composting facilities where they are turned into fertilizer, reused in our landscaping and provided to employees for use at home.

Greening Our Cafés: In Cambridge, San Diego and RTP, we introduced compostable products in our cafés and encourage employees to use reusable containers.

Modeling Waste Reduction in Hillerød, Denmark: We created a database that helps employees determine which recycling or waste container to use for different waste streams and where they are located. The database also provides specific steps for the responsible disposal or treatment of each waste stream.

Green Chemistry and Product Lifecycle >>

We are working to lessen the impacts of our products over their lifecycle.

Improving Lifecycle Impact with Green Chemistry: We established a Green Chemistry Committee to create seminars, trainings, informational materials and projects that improve the efficiency, safety and environmental impact of chemical use in the development of our drugs.

Ensuring Responsible Supply Chain Management: We were the first biotechnology company to join the Carbon Disclosure Project Supply Chain and one of the first to join the Pharmaceutical Supply Chain Initiative. In these groups, we meet with peers to share lessons and drive sustainable business practices.



Landscaper applies compost generated from buffered solutions.



Newsweek's 2009 Green Rankings

Ranked 1 of 18 in Pharmaceutical Sector for Lowest Environmental Impact.

Ranked 13 of 18 in Pharmaceutical Sector overall.

CARBON DISCLOSURE PROJECT

Carbon Disclosure Project 2009 Report

Ranked in the top five in both the FTSE Global Equity Index 500 and S&P 500 Healthcare categories based on our continued improvement of monitoring and understanding of our potential risk associated with climate change.

Society



The **Society** focus of sustainability at Biogen Idec encompasses every interaction between our employees and our stakeholders. It goes beyond addressing unmet medical needs to providing educational and other support services for our patients, offering a supportive and challenging work environment to our employees, and giving back to the communities in which we live and work.



Medicines for Unmet Needs ▶▶

Biogen Idec's expertise in biologics and our growing pipeline in pharmaceuticals enable us to deliver first-in-class or best-in-class molecules that ultimately enhance our patients' quality of life. We also collaborate with other biotechnology and pharmaceutical companies to develop and distribute therapies. Through our work, we touch countless lives, striving to extend and improve them for the better.

Patient Safety and Transparency ▶▶

We approach research and development in a focused and strategic manner and are committed to continually developing and advancing our approach to better carry out our mission.

Identifying and developing new or improved therapies to address serious unmet medical needs is a long process. Most discoveries never make it to market; on average, for every 10,000 compounds identified, only one will be approved for use.

The U.S. Food and Drug Administration and its equivalent counterparts in other countries regulate the development of new drugs and mandate that all new therapies undergo a stringent process of preclinical and clinical evaluation to ensure they are safe and effective. For more detail on the steps for developing and delivering a new therapy to market, please see the "Research and Development" section of www.biogenidec.com.

While our products provide life-changing benefits, they may create health risks for some patients. We are committed to disclosing the benefits and risks of our products to physicians and patients so they can make informed treatment choices. We have placed information for patients to assess the benefits and risks of our therapies at www.biogenidec.com. Specific information about clinical trials under way is available at www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.



Total Value of Financial Assistance Provided, 2007 – 2009

Year	2007	2008	2009
Patients Served	8,000	12,000	18,000
Total Donated (in millions)	\$100	\$140	\$230



Ensuring the Humane Treatment of Animals ▶▶

Regulations mandate the testing of potential therapeutics in animals. We are committed to complying with all applicable animal welfare regulations and have established Institutional Animal Care and Use Committees to provide oversight for animal care and use at our facilities. This includes work to reduce the number of animals used in testing, refine the methods used to minimize discomfort, and replace the use of animals with other methods of testing whenever possible.

All of our animal facilities are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. We also require any contractors using animals in research to meet our animal-welfare standards.

Drug Pricing ▶▶

We strive to ensure fair pricing of our therapies. Many factors influence the price of our drugs, including the price of competitive products in the marketplace, research and development investments, operation costs and return to our shareholders. In cases where patients are unable to afford therapies, we are committed to helping them obtain our products through our Patient Assistance Program.

Access to Medicine ▶▶

Biogen Idec provides assistance to patients as they navigate the complexities of their insurance coverage and request financial assistance. We leverage many different resources to help patients obtain free or discounted medications, including:

- Helping identify and refer patients to charitable organizations that support those who have a financial need;
- Enrolling eligible patients in our CoPay Assistance Programs where patients may pay as little as \$10 a month for their drug costs; and
- Providing free drugs to eligible patients through our free drug program.

Marketing Practices ▶▶

We are committed to providing information that is accurate, supported by scientific evidence, and in every context, presented honestly and fairly. Our interactions with our patients and health-care providers are governed by laws and regulations, as well as our Code of Business Conduct and our Comprehensive Compliance Program, which can be found on the “About Us” section of www.biogenidec.com. All applicable employees undergo regular training and education programs regarding our marketing policies and practices.

Workplace Culture ▶▶

At Biogen Idec, we strive to foster a culture that is inspiring, collaborative and fulfilling. We want our employees to be proud of the role they play in developing life-changing therapies and to know that Biogen Idec is a company where they can develop their careers and make meaningful contributions to our mission of “transforming discovery into care.”

Biogen Idec Total Rewards: Your Money, Your Health, Your Career, Your Life ▶▶

Biogen Idec provides our employees with a comprehensive Total Rewards program that is focused on what matters most to them – their health, financial well-being, career development and work-life balance. Our compensation programs are reviewed annually to ensure competitive pay and include short-term and long-term incentives at every job level. In addition, we offer a highly competitive retirement savings program, financial education services, comprehensive health-care programs and income protection programs, such as life and disability insurance. We also offer individual and family support programs designed to help employees handle life’s daily challenges, as well as work-life programs, such as tuition reimbursement and commuter benefits.

Employee Satisfaction ▶▶

We value and respect our employees’ input and encourage them to share their thoughts and concerns. In 2009, we surveyed a representative sample of our employees to determine their satisfaction with working at Biogen Idec and found that:

- 97 percent of employees are proud to be associated with Biogen Idec.
- 93 percent would recommend Biogen Idec as a good place to work.

We were pleased to learn that on these and almost every other survey measure, Biogen Idec ranked well ahead of global life-science industry averages. We believe that the high level of employee satisfaction has been the main driver of our low turnover rate, which was 4.2 percent in 2009.

Fostering Diversity ▶▶

Biogen Idec strives to build diverse teams that leverage the expertise, experience and perspective of each team member. In particular, we aim to provide attractive employment opportunities for minorities and women at all levels and in all segments of our organization. We also work to sustain meaningful relationships with candidate sources, community organizations and academic institutions to actively attract and recruit diverse candidates to our organization.



Great Place to Work® Institute

Our International Headquarters in Zug, Switzerland, was named one of the 2009 “Best Workplaces” by the Great Place to Work® Institute.

Workforce Development >>

We are committed to the professional development of our employees and offer a number of programs to help them maximize their potential, including:

Development Planning: We provide resources for managers and employees to use in creating career-development goals.

Leadership Institute: Our Leadership Institute provides leadership, management and professional learning opportunities to United States-based employees. We offer a tailored curriculum and courses to help employees at all levels plan their development, grow their careers and build their capabilities. In 2009, we offered over 25 different courses and led 250 sessions at our campuses nation-wide, enrolling nearly half of our United States-based employees.

Recognizing and Rewarding Our Employees >>

At Biogen Idec, we recognize our employees' performance through merit-based bonuses and pay raises. Additionally, we have several recognition programs that celebrate employees' achievements.

APPLAUSE Recognition Program: This peer-to-peer recognition program rewards outstanding performance, ranging from an e-card thank you to awards up to \$3,000 in value.

Annual Leadership Award: We provide recognition to employees who consistently exemplify our Core Values.

Service Awards: We recognize our long-service employees for continued commitment to Biogen Idec with a range of awards, depending on the length of employment.

Ensuring Employee Health and Safety >>

Biogen Idec is committed to maintaining a healthy and safe work environment. We have adopted a formal health and safety management system, which we update regularly to keep pace with the changing requirements of our business. We also require all employees to attend safety classes specifically tailored to their lines of work.




Cultivating Talent: From the Community Lab to Biogen Idec Employee

Subnam Kapadia first visited a Biogen Idec Community Lab as a high school freshman. Today, she is one of our newest employees and the first former Community Lab student to be hired by Biogen Idec.

"I don't know where I would be without the Community Lab. I learned a lot in school, but without hands-on experience, it would not have had the same effect," she says. "Having access to the resources and mentors in the Community Lab hardened my desire to go into the sciences in a way that book learning alone could not have inspired."

Learn more about our Community Labs on the following page.

Days Away Case Rate



This chart presents our Days Away Case Rate. It counts injury and illness cases involving days away from work.



Philanthropy >>

We believe it is our responsibility to advance care and improve life for everyone our business touches. Our biggest philanthropic effort is to ensure that people who need our therapies and services are financially able to access them (for more information, see page 12). Additionally, between 2006 and 2009, we gave more than \$48 million to support communities globally.

Biogen Idec Philanthropic Contributions

Year	2006	2007	2008	2009
Giving (in millions)	\$11.825	\$11.080	\$11.621	\$13.641

The Biogen Idec Foundation >>

The Biogen Idec Foundation's mission is to improve the quality of people's lives and contribute to the vitality of communities where we operate in the United States, with an emphasis on promoting science literacy and encouraging young people to consider science careers. The Foundation also supports Biogen Idec's employee academic matching gifts program. For more information on our Foundation, please visit the "Corporate Citizenship" section of www.biogenidec.com.

Biogen Idec Community Labs >>

Located within the company's Cambridge and San Diego research buildings, Biogen Idec Community Labs provide hands-on instruction to local middle and high school students and teachers. Through the Labs, Biogen Idec employees help students conduct real-world experiments, providing insights into what it is like to work at a leading biotechnology company. To date, more than 600 Biogen Idec employees have volunteered, reaching more than 21,000 students.

Supporting Patient and Provider Communities >>

We strive to support all people and families who suffer from MS, lymphoma and rheumatoid arthritis. We provide educational grants for medical, scientific and patient activities, which educate health-care professionals and patients about the diseases Biogen Idec treats. We also contribute to major nonprofits that work in these areas, such as the National Multiple Sclerosis Society, to help them educate and support their communities.

Advancing Academic Research and Knowledge >>

We support universities around the world to educate health-care providers and scientists. Since 2006, we have provided annual fellowship grants through our MS Clinical Fellowship Program to advance MS care at leading institutions, and we anticipate growing this program in the future.

RTP Employees Walk for Multiple Sclerosis

Each year, employees at Biogen Idec's RTP campus in North Carolina participate in the Triangle Walk MS to benefit the North Carolina regional chapter of the National Multiple Sclerosis Society. In 2009, the team had 557 walkers, including friends and family, the most of any team at the walk and one of the largest in the nation. It raised nearly \$35,000 to support the MS community.



Statement

This booklet was printed using certified wind power on paper that contains 100 percent post-consumer recycled fiber.

According to The Environmental Defense Fund, a leading environmental organization, by using 100 percent post-consumer recycled fiber in the production of this piece, Biogen Idec has saved 1 tree, 117 pounds of carbon dioxide, 563 gallons of waste water and 34 pounds of solid waste.

Produced with Certified
WIND POWER



Please visit Biogen Idec at
www.biogenidec.com
for more information about us.

To provide feedback, please e-mail:
corporatcitizenshipreport@biogenidec.com.